Faculty

Faculty

Panelists

Disclosures

Disclosures (cont)

Target Audience and Learning Objectives

Metastatic Colorectal Cancer (mCRC)

mCRC: Resectable

mCRC: (R)evolution

mCRC: (R)evolution (cont)

mCRC: Approved/Investigational Drugs

mCRC: Past, Present, and Future

mCRC: Targeted Therapy — Anti-Angiogenic

mCRC: Targeted Therapy — Anti-EGFR Biomarkers

mCRC: RAS Mutation Status

mCRC: Case Example

mCRC: Chemotherapy for Diffuse Metastatic Disease

mCRC: Chemotherapy for Diffuse Metastatic Disease cont

mCRC: Current Options for Addition of Biological Agent

mCRC: Treatment Options According to Clinical Criteria

mCRC: Which Frontline Regimen Should Be Used?

mCRC: Treatment Strategy

mCRC: Case Example: Progressing Disease With First- and Second-line

Therapy

Angiogenesis and Cancer: Rebound Effect

Anti-Angiogenesis and mCRC: Beyond Progression

Anti-angiogenesis and mCRC: Beyond Progression (Preclinical

Studies)

Anti-angiogenesis and mCRC: Beyond Progression

(preclinical data)

Anti-angiogenesis and mCRC: Beyond Progression (Clinical Data)

mCRC Strategies: Consolidation/Maintenance

Treatment

Consolidation/Maintenance Treatment — Timing and Efficacy

Consolidation/Maintenance Treatment — CAIRO3

Biomarker Status Over Time

mCRC: Serial Biomarker Testing

mCRC: Metabolic Imaging

mCRC: Liquid Biopsy - Following Changes in Genomic Status

mCRC: Dynamic Biomarker Study (UK)

Team Approach to Oncologic Therapy

Case Presentation, Part 1

Patient Case, Part 1: History

Patient Case, Part 1: Presentation and Findings

Patient Case, Part 1: Imaging and Laboratory Findings

Patient Case, Part 1: Clinical Considerations

Patient Case, Part 1: Treatment Options

Patient Case, Part 1: Initial Treatment and Instructions

Patient Case, Part 1: Response to Treatment

Patient Case, Part 1: Progression on Maintenance Therapy

Discussion (Part 1)Fortunato Ciardiello, MD; Marc

Peeters, MD, PhD

Case Presentation, Part 2

Patient Case, Part 2: First Relapse

Patient Case, Part 2: Laboratory Findings

Patient Case, Part 2: Patient Goals and Clinical Considerations

Patient Case, Part 2: Treatment Options

Patient Case, Part 2: Treatment and Patient Instructions

Patient Case, Part 2: FOLFIRI + Ziv-Aflibercept — Response

Discussion (Part 2)Fortunato Ciardiello, MD; Marc

Peeters, MD, PhD

Case Presentation, Part 3

Patient Case, Part 3: Disease Progression — Considerations

Patient Case, Part 3: Disease Progression — Considerations

Patient Case, Part 3: Disease Progression — Oxaliplatin…Again?

Patient Case, Part 3: Disease Progression — Local Therapies?

Patient Case, Part 3: Disease Progression — Regorafenib?

Patient Case, Part 3: Regorafenib - Administration

Patient Case, Part 3: Regorafenib - Administration

Discussion (Part 3) Fortunato Ciardiello, MD; Marc

Peeters, MD, PhD

Team Approach to Oncologic Therapy

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)